Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: IM/SC Female Infertility Daily dose providing 75-150 u FSH. Adjust dose gradually till adequate response. Once reached, stop menotrophin and induce ovulation w/ chorionic gonadotrophin 1-2 days later. In menstruating patients, start treatment w/in the 1st 7 days of the menstrual cycle; may repeat cycle at least twice more if needed. In vitro fertilisation procedures or other assisted conception techniques As monotherapy or w/ clomiphene citrate or gonadorelin agonist: Daily dose providing 75-300 u FSH, usually started on the 2nd or 3rd of the menstrual cycle and continued till adequate response is obtained, followed by chorionic gonadotrophin 1-2 days after the last menotrophin inj only if there are ≥3 follicles >17 mm in diameter w/ 17-β-oestradiol levels ≥3,500 pmol/L. Male infertility W/ chorionic gonadotrophin: Dose providing 75 or 150 u FSH 2-3 times wkly, continue treatment for ≥3-4 mth.
Pregnancy & lactation. Ovarian cysts or enlarged ovaries (not due to polycystic ovarian syndrome), uncontrolled thyroid and adrenal dysfunction, organic intracranial lesions (e.g. pituitary tumours), abnormal genital bleeding of unknown cause, presence of other causes of infertility other than anovulation (unless they are candidates of in vitro-fertilisation), hormone sensitive tumours e.g. breast, uterus, prostate, ovaries or testes. Primary ovarian failure, malformation of sexual organs or fibroid tumours of the uterus incompatible with pregnancy, structural abnormalities such as tubal occlusion (unless superovulation is to be induced), ovarian dysgenesis, absent uterus or premature menopause.
Special Precautions
In females: Monitor ovarian activity and measure urinary oestrogen at regular intervals, until stimulation occurs. Discontinue menotrophin treatment and withhold human chorionic gonadotrophin if urinary oestrogen levels >540 nmol/24 hr, or if plasma 17 β-oestradiol levels >3000 pmol/l, or if there is any sharp rise in values. Refrain from sexual intercourse or use barrier contraception methods for at least 4 days and pelvic examinations to be avoided or carried out with care.
Adverse Reactions
Ovarian enlargement, ovarian cysts, enlarged abdomen, GI disturbances (e.g. nausea, vomiting, diarrhoea, abdominal pain or cramps, bloating), inj site reactions, headache, dizziness, tachycardia, dyspnoea, tachypnoea, hypersensitivity reactions. Multiple births and miscarriages.
Potentially Fatal: Ovarian Hyperstimulation Syndrome, severe pulmonary conditions (e.g atelectasis, acute respiratory distress syndrome) and thromboembolic events.
Drug Interactions
Increased follicular response with clomiphene citrate. Higher dose of menotrophin needed when gonadotropin-releasing hormone agonist is used for pituitary desensitisation.
Disclaimer: This information is independently developed by CIMS based on menotrophin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in